Epidemiological Survey of Cardiometabolic Multimorbidity and Related Risk Factors in Chinese Population: A Cross-Sectional Study

Author:

Xu Siying1,Wang Wenbin2,Wang Jiabin3,Cai Anping2,Jiang Xiaofei4,Feng Yingqing1

Affiliation:

1. Zhuhai hospital affiliated with Jinan University (Zhuhai People's Hospital)

2. Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences

3. Guangdong Academy of Medical Sciences

4. Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University)

Abstract

Abstract Background The widespread prevalence of Cardiometabolic Multimorbidity (CMM) presents significant challenges to global public health. While previous studies have primarily examined individual cardiometabolic diseases, there has been limited research on CMM. As such, we intend to assess the prevalence of CMM and identify predictive risk factors within the Chinese population which will hold considerable implications for the future management of CMM. Methods We employed data from The China Patient-Centered Evaluative Assessment of Cardiac Events Million Persons Project (China-PEACE MPP), enrolling a total of 102,358 participants aged 35–75 years. CMM was defined as the simultaneous presence of two or more of the following diseases: diabetes, hypertension, stroke, and coronary heart disease. Univariate and multivariate logistic regression analyses were performed on demographic variables and modifiable factors associated with CMM to identify its risk predictive factors. Results The participants, with an average age of 54.27 years, comprised 60.5% of women. The overall prevalence of CMM was 11.6%, with hypertension and diabetes coexisting as the most common comorbid combination at 8.5%. Multifactor logistic regression analysis revealed that increasing age (45–54 years (OR = 2.62, 95%CI: 2.39–2.88), 55–64 years (OR = 5.27, 95%CI: 4.83–5.78), and 65–75 years (OR = 8.36, 95%CI: 7.62–9.18) compared to 35–44 years), current alcohol consumption (OR = 1.23, 95%CI: 1.12–1.34), TG ≥ 2.3mmol/L (OR = 1.69, 95%CI: 1.61–1.78), recent use of lipid-lowering medications (OR = 3.47, 95%CI: 3.21–3.74), and recent use of antiplatelet aggregators (OR = 3.67, 95%CI: 3.33–4.04) were associated with an increased risk of CMM. Conversely, a reduced occurrence of CMM was associated with being female (OR = 0.74, 95%CI: 0.70–0.78), other marital statuses (OR = 0.91, 95%CI: 0.85–0.97), education level of high school or above (OR = 0.90, 95%CI: 0.85–0.94), annual household income not less than 50,000 yuan (OR = 0.93, 95% CI: 0.89–0.98, p = 0.004), and HDL-C ≥ 1.0mmol/L (OR = 0.84, 95%CI: 0.79–0.90). Conclusions In the general population of China, over one-tenth of individuals are affected by CMM, indicating a high current prevalence of the condition. This highlights the imperative for China to develop targeted intervention measures focusing on the risk factors of CMM to prevent its occurrence and progression, effectively manage the condition, and reduce associated adverse outcomes and healthcare resource consumption.

Publisher

Research Square Platform LLC

Reference56 articles.

1. Association between cardiometabolic disease multimorbidity and all-cause mortality in 2 million women and men registered in UK general practices;Canoy D;BMC Med,2021

2. Association of Cardiometabolic Multimorbidity With Mortality;Angelantonio E;JAMA,2015

3. Multimorbidity of cardiometabolic diseases: prevalence and risk for mortality from one million Chinese adults in a longitudinal cohort study;Zhang D;BMJ Open,2019

4. Frailty, an Independent Risk Factor in Progression Trajectory of Cardiometabolic Multimorbidity: A Prospective Study of UK Biobank;Ma T;J Gerontol A Biol Sci Med Sci,2023

5. Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression;Dove A;Alzheimers Dement,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3